XVIVO

XVIVO
Clinically optimised solutions and systems for transplantation
XPS™
The first medical device approved by the US FDA for ex vivo lung perfusion (EVLP) of initially rejected donor lungs
- Extensive clinical practice, based on expertise and experience from clinicians
- Developed with daily clinical challenges in mind
Read more
Our vision
Nobody Should Die Waiting For A New Organ
Learn More

February 17, 2021 Primeur in UZ Leuven: nieuwe techniek om donorhart te vervoeren zorgt voor minder schade na transplantatie
February 17, 2021 Primeur voor UZ Leuven: eerste Belgische patiënt krijgt harttransplantatie met nieuwe bewaringstechniek
November 5, 2020 Fun with the Maryland STEM Festival – Working on Lungs outside the body (mentioned in description)
July 1, 2020 Health Beat: New and improved donated lungs
October 11, 2019 New transplant research aims to salvage infected donated organs
August 16, 2019 'Really gives me hope': New technology expected to increase number of lung transplants in B.C.

Learn more about our abdominal product line Click here

XVIVO helps transplant surgeons and perfusionists to increase operating room efficiency
XVIVO offers transplant centers and clinics a research focused and reliable EVLP-partner
XVIVO products facilitate an optimal use of available donor organs

Innovation for transplantation

XVIVO is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation and perfusion in connection with transplantation. The company is firmly rooted in medical science.

We collaborate with transplant teams to save lives. Our mission is to increase the survival rates of patients awaiting transplantation by supporting transplant teams in every way we can. We join forces with the transplant teams to give more patients a better life. We provide our customers with solutions and systems that can improve the transplant process outcome and expand the pool of transplantable organs.